Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

China Medical System Licenses Teikoku’s Lidoderm for Postherpetic Neuralgia in China

Fineline Cube Feb 13, 2026
Company Deals

Salubris Pharma Files Hong Kong IPO for Secondary Listing to Expand Cardiorenal Metabolic Franchise

Fineline Cube Feb 13, 2026
Company Deals

Immunofoco Bio Files Hong Kong IPO for Solid Tumor CAR-T Pipeline

Fineline Cube Feb 13, 2026
Company Deals

Ribo Life Science Licenses $4.4 Billion MASH siRNA Portfolio to Madrigal Pharmaceuticals

Fineline Cube Feb 12, 2026
Company Deals

Novartis Secures Long-Term Actinium-225 Supply from Niowave for Radioligand Therapy Expansion

Fineline Cube Feb 12, 2026
Policy / Regulatory

FDA Cracks Down on Compounded GLP-1 APIs; Novo Nordisk Sues Hims & Hers for Patent Infringement

Fineline Cube Feb 11, 2026
Company Drug

Amgen’s UPLIZNA Wins European Approval for Generalized Myasthenia Gravis

Fineline Cube Feb 13, 2026
Company Drug

Innovent Biologics Initiates Phase 3 HeriCare-Breast01 Study for IBI354 in HER2+ Breast Cancer

Fineline Cube Feb 13, 2026
Company Drug

Simcere’s SIM0237 Begins Clinical Study for PD-L1 and IL-15 Targeting Bispecific Antibody

Fineline Cube Mar 10, 2023

China-based Simcere Pharmaceutical Group (HKG: 2096) has announced the first patient in (FPI) a clinical...

Deals Drug

AusperBio and Asymchem Form Strategic Partnership for Drug Development

Fineline Cube Mar 10, 2023

China-based firms AusperBio and Asymchem (SHE: 002821, HKG: 6821) have entered into a strategic partnership...

Policy / Regulatory

NHSA’s 2022 Healthcare Security Bulletin Reveals Break-Even Performance

Fineline Cube Mar 10, 2023

The National Healthcare Security Administration (NHSA) has released its annual “Healthcare Security Development Statistical Bulletin”...

Company Drug

Bio-Thera Solutions Initiates Phase I Study for Trop2-Targeting ADC BAT8008

Fineline Cube Mar 10, 2023

China-based Bio-Thera Solutions, Ltd (SHA: 688177) has announced the first patient dosing in a multi-center,...

Company Drug

Astellas and Seagen File for NMPA Approval of Enfortumab Vedotin for Urothelial Carcinoma

Fineline Cube Mar 10, 2023

Japan-based Astellas Pharma Inc. (TYO: 4503) and US biotech Seagen Inc. (Nasdaq: SGEN) have announced...

Company Deals

HuiLiao Biomedical Raises RMB 100 Million in Pre-Series A Round for mRNA Development

Fineline Cube Mar 10, 2023

China-based nucleic acid drug specialist Suzhou HuiLiao Biomedical Technology Co., Ltd has reportedly raised over...

Company Drug

InnoCare Pharma Initiates Clinical Study for BCL2 Inhibitor ICP-248 in China

Fineline Cube Mar 10, 2023

China-based InnoCare Pharma (HKG: 9969, SHA: 688428) has announced the first subject dosing in a...

Company Deals

Thederma Pharmaceuticals Raises RMB 100 Million for AhR-Targeted Therapies

Fineline Cube Mar 10, 2023

China-based Shanghai Thederma Pharmaceuticals Co., Ltd has reportedly raised RMB 100 million (USD 14.35 million)...

Company Deals

Xinrui Medtech Secures Pre-Series A Funding for Cardiovascular Device Development

Fineline Cube Mar 10, 2023

Xinrui Medtech, a cardiovascular device maker based in Suzhou, has reportedly raised “tens of millions”...

Company Medical Device

Lifetech Scientific’s IBS Angel Stent Receives CE MDR Certification in EU

Fineline Cube Mar 10, 2023

China-based Lifetech Scientific Corporation (HKG: 1302) has announced that it has received CE MDR certification...

Company Deals

Olipharma Raises Funds in Pre-Series A+ Round to Expand Manufacturing Facilities

Fineline Cube Mar 10, 2023

Olipharma, a small nucleic acid drug Contract Development and Manufacturing Organization (CDMO) based in Suzhou,...

Company Drug

Inventiva and Chia Tai Tianqing File Clinical Trial for Lanifibranor with CDE

Fineline Cube Mar 10, 2023

France-based Inventiva S.A. and China’s Chia Tai Tianqing have filed a clinical trial application with...

Company Drug

Simcere Pharmaceutical Initiates Clinical Study for Bispecific Antibody SIM0237 in Advanced Tumors

Fineline Cube Mar 10, 2023

China-based Simcere Pharmaceutical Group (HKG: 2096) has announced the first patient in (FPI) a clinical...

Company Deals

AusperBio and Asymchem Form Strategic Partnership for New Drug R&D and Services

Fineline Cube Mar 10, 2023

China-based firms AusperBio and Asymchem (SHE: 002821, HKG: 6821) have entered into a strategic partnership...

Policy / Regulatory

NHSA’s 2022 Healthcare Security Report Reveals Break-Even Performance

Fineline Cube Mar 10, 2023

The National Healthcare Security Administration (NHSA) has released its annual “Healthcare Security Development Statistical Bulletin”...

Company Drug

Bio-Thera Solutions Initiates Phase I Study for Trop2-Targeting ADC BAT8008

Fineline Cube Mar 10, 2023

China-based Bio-Thera Solutions, Ltd (SHA: 688177) has announced the first patient dosing in a multi-center,...

Company Drug

Astellas and Seagen File for NMPA Approval of Enfortumab Vedotin for Urothelial Carcinoma

Fineline Cube Mar 10, 2023

Japan-based Astellas Pharma Inc. (TYO: 4503) and US biotech Seagen Inc. (Nasdaq: SGEN) have announced...

Company Deals

HealiRNA Secures RMB 100 Million in Pre-Series A Funding for Nucleic Acid Drug Development

Fineline Cube Mar 10, 2023

China-based nucleic acid drug specialist Suzhou HealiRNA has reportedly raised over RMB 100 million (USD...

Company Drug

InnoCare Pharma Initiates Clinical Study for BCL2 Inhibitor ICP-248 in China

Fineline Cube Mar 10, 2023

China-based InnoCare Pharma (HKG: 9969, SHA: 688428) has announced the first subject dosing in a...

Company Deals

Thederma Pharmaceuticals Raises RMB 100 Million for AhR-Targeted Autoimmune Therapies

Fineline Cube Mar 10, 2023

China-based Shanghai Thederma Pharmaceuticals Co., Ltd has reportedly raised RMB 100 million (USD 14.35 million)...

Posts pagination

1 … 511 512 513 … 624

Recent updates

  • CARsgen Therapeutics to Invest $54 Million in Shanghai CAR-T Manufacturing Facility
  • GSK Reports 7% Revenue Growth to $44.7 Billion in 2025; Oncology Surges 43%
  • Novocure’s Optune Pax Wins FDA Approval for Pancreatic Cancer; Zai Lab China Rights in Play
  • China Medical System Licenses Teikoku’s Lidoderm for Postherpetic Neuralgia in China
  • Organon Reports 2025 Revenue Decline to $6.2 Billion; JADA Sale and Portfolio Pressures Weigh
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company

CARsgen Therapeutics to Invest $54 Million in Shanghai CAR-T Manufacturing Facility

Company

GSK Reports 7% Revenue Growth to $44.7 Billion in 2025; Oncology Surges 43%

Company Medical Device

Novocure’s Optune Pax Wins FDA Approval for Pancreatic Cancer; Zai Lab China Rights in Play

Company Deals

China Medical System Licenses Teikoku’s Lidoderm for Postherpetic Neuralgia in China

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.